Your browser has either disabled or does not support javascript. Javascript is required for full website experience.
Biogen Inc.
BIIB
$
276.63
-33%
Sun June 13th, 2021
16:35
Analysis
Sesen Bio: Binary Event Approaching
Seeking Alpha
Sat June 12th, 2021
14:10
Analysis
Stocks To Watch: FOMC Takes Center Stage, Hedge Funds Pitch And E3
Seeking Alpha
Fri June 11th, 2021
19:56
Analysis
Investors Shrug Off Inflation, For Now
Seeking Alpha
16:37
Digest
Stocks making the biggest moves midday: Chewy, Biogen, Snowflake and more
CNBC
10:45
Analysis
Guide
Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments
The Motley Fool
Thu June 10th, 2021
23:18
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
What comes next after the Biogen Alzheimer’s drug approval
Fortune
21:14
Third member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drug
CNBC
20:19
Analysis
Why Biogen, Lilly, and Prothena Stocks Soared This Week
The Motley Fool
18:49
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
Biogen's Alzheimer's drug could cost Medicare billions of dollars a year, report finds
CNBC
13:30
Analysis
Biotechs Ready To Roar
Seeking Alpha
Tue June 8th, 2021
23:33
Analysis
Biogen Sinks Despite Raft of Analyst Upgrades
The Motley Fool
19:18
Analysis
Senator Takes Aim at Biogen's New Alzheimer's Drug
The Motley Fool
17:26
Biogen/Alzheimer’s: the high cost of hope
Financial Times
16:39
Digest
Stocks making the biggest moves midday: Clover, Stitch Fix, Biogen and more
CNBC
16:07
Analysis
Biogen's Aducanumab Approval: Making The Advisory Committee Irrelevant
Seeking Alpha
15:53
Analysis
Biogen faces tough questions over $56K-a-year price of newly approved Alzheimer's drug
CNBC
+ 2 more
14:15
Analysis
Guide
The Aducanumab Approval
Seeking Alpha
14:09
Pharma, Biotech Stocks Start Week With A Bang After Biogen's Alzheimer's Approval
Benzinga
12:41
Analysis
How The FDA Got It Wrong In Approving Biogen's Aducanumab For Alzheimer's Disease
Seeking Alpha
11:27
Analysis
Digest
Wall Street Breakfast: Memorable Approval
Seeking Alpha
10:03
Analysis
Could Biogen Be a Millionaire-Maker Stock?
The Motley Fool
09:52
Analysis
Guide
Should You Buy Biogen Stock After Its Stunning FDA Win?
The Motley Fool
04:00
Biogen’s $56,000-a-year Alzheimer’s drug reignites US debate over costs
Financial Times
00:21
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
Dementia expert says evidence behind Biogen Alzheimer's drug 'wasn’t sufficient' for FDA approval
CNBC
Mon June 7th, 2021
22:12
Analysis
Biogen's New Alzheimer's Drug Will Cost $56,000 Per Year
The Motley Fool
19:48
Analysis
Biogen CEO says $56,000 annually for Alzheimer’s drug is 'fair,' promises not to hike price for at least 4 years
CNBC
+ 1 more
17:48
Analysis
Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich
The Motley Fool
17:17
Biogen's Alzheimer's Drug is a Wall Street Winner
Wall Street Journal
16:45
Analysis
Biogen's Alzheimer's Disease Treatment Earns FDA Approval
The Motley Fool
+ 1 more
13:31
Press Releases
Analysis
Thinking about trading options or stock in Biogen, Tilray, Moderna, Walt Disney, or Apple?
PR Newswire
11:06
Analysis
Digest
Wall Street Breakfast: Global Tax Deal
Seeking Alpha
Fri June 4th, 2021
19:25
Digest
Stocks making the biggest moves midday: Square, Biogen, DocuSign and more
CNBC
15:11
Analysis
A Brief Note About Aducanumab
Seeking Alpha
14:30
Analysis
Pushing My Chips In On Biogen Before FDA Judgement Day
Seeking Alpha
Wed June 2nd, 2021
20:00
Analysis
Here's the Biggest Challenge Biogen Will Face if Its Alzheimer's Drug Is Approved
The Motley Fool
Thu May 27th, 2021
11:45
Analysis
Is Biogen a Buy?
The Motley Fool
Fri May 21st, 2021
12:30
Press Releases
Global $14.1 Billion Oligonucleotide Synthesis Market to 2026 Featuring Therapeutic Players - Biogen, Sarepta Therapeutics, Ionis Pharmaceuticals, & Alnylam Pharmaceuticals
PR Newswire
Wed May 19th, 2021
02:24
Analysis
Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q1 2021 Update
Seeking Alpha
Fri May 14th, 2021
13:41
Analysis
Alzheimer's Is Becoming The Ultimate Battlefield In Biopharma, Creating Unprecedented Value And Opportunity For Investors
Seeking Alpha
12:30
Biogen's Retinal Disease Gene Therapy Flunks Mid-Stage Study
Benzinga
